Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease.

"availability of data and materials all rna-seq data have been submitted to the gene expression omnibus (geo) under accession number gse241257. availability of data and materials all rna-seq data have been submitted to the gene expression omnibus (geo) under accession number gse241257"

"Declarations Ethics approval and consent to participateThe Institutional Review Board (IRB) of Yongin Severance Hospital approved the study (IRB No. 9-2021-0122), and patients did not need to provide informed consent as the data used was publicly available from NHIS. All animal procedures were according to the guidelines established by the Ajou University School of Medicine Ethics Review Committee (IACUC No. 2022-0013). Consent for publicationNot applicable. Competing interestsJBK, YK, SJK, TYH, DKK, MS, DY, and SMP are inventors of patents related to this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest. Competing interests JBK, YK, SJK, TYH, DKK, MS, DY, and SMP are inventors of patents related to this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest."

"Funding This research was supported by the National Research Foundation of Korea (NRF) grants funded by the Korean government (Ministry of Science and ICT) (Grant No. NRF-2019R1A5A2026045)."